Journal of clinical and experimental hematopathology : JCEH最新文献_第9页

Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events. 布伦妥昔单抗维多汀治疗霍奇金淋巴瘤患者，由于胆管消失综合征导致肝功能障碍，导致部分反应，无任何严重不良事件。

IF 1.5

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2022-09-28 Epub Date: 2022-07-12 DOI: 10.3960/jslrt.21035

Kantaro Ishitsuka, Yasuhisa Yokoyama, Naoko Baba, Ryota Matsuoka, Noriaki Sakamoto, Tatsuhiro Sakamoto, Manabu Kusakabe, Takayasu Kato, Naoki Kurita, Hidekazu Nishikii, Mamiko Sakata-Yanagimoto, Naoshi Obara, Yuichi Hasegawa, Shigeru Chiba

{"title":"Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events.","authors":"Kantaro Ishitsuka, Yasuhisa Yokoyama, Naoko Baba, Ryota Matsuoka, Noriaki Sakamoto, Tatsuhiro Sakamoto, Manabu Kusakabe, Takayasu Kato, Naoki Kurita, Hidekazu Nishikii, Mamiko Sakata-Yanagimoto, Naoshi Obara, Yuichi Hasegawa, Shigeru Chiba","doi":"10.3960/jslrt.21035","DOIUrl":"https://doi.org/10.3960/jslrt.21035","url":null,"abstract":"Vanishing bile duct syndrome (VBDS) is a rare hepatic disorder which leads to liver failure as a result of progressive destruction of the intrahepatic bile ducts. There are no treatment modalities for VBDS itself and severe hepatic dysfunction restricts the treatment of underlying diseases. We safely treated a case of classic Hodgkin lymphoma (HL) with VBDS using brentuximab vedotin (BV). The patient was treated with 5 cycles of reduced BV and a partial metabolic response was obtained. Moreover, a standard dose of BV for another 5 cycles was accomplished with minimal adverse events. Our experience indicates that BV could be a treatment option for classic HL with VBDS.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"154-157"},"PeriodicalIF":1.5,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ac/b8/jslrt-62-154.PMC9635035.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40600808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Addition of bortezomib to high-dose cyclophosphamide therapy as a conditioning regimen for autologous peripheral blood stem cell harvest leads to an increased yield of hematopoietic stem cells. 在高剂量环磷酰胺治疗中加入硼替佐米作为自体外周血干细胞收获的调理方案，可增加造血干细胞的产量。

IF 1.5

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2022-09-28 Epub Date: 2022-08-18 DOI: 10.3960/jslrt.22013

Sayaka Ohno, Kiyohito Hayashi, Ryo Shimizu, Akihiro Ishii, Hiroaki Tanaka

{"title":"Addition of bortezomib to high-dose cyclophosphamide therapy as a conditioning regimen for autologous peripheral blood stem cell harvest leads to an increased yield of hematopoietic stem cells.","authors":"Sayaka Ohno, Kiyohito Hayashi, Ryo Shimizu, Akihiro Ishii, Hiroaki Tanaka","doi":"10.3960/jslrt.22013","DOIUrl":"https://doi.org/10.3960/jslrt.22013","url":null,"abstract":"Peripheral blood stem cell harvest (PBSCH) is a crucial procedure for autologous stem cell transplantation in patients with multiple myeloma. We herein report a retrospective study to verify the usefulness of bortezomib and high-dose cyclophosphamide therapy (Bor-HDCY) as a conditioning regimen for PBSCH. Thirty-three patients were evaluated. The median age at the first apheresis was 61 (interquartile range, 53-64) years old, and 18 (54.5%) patients were male. Bor-HDCY was performed in 15 patients, and HDCY was performed in 18. In the patients who underwent Bor-HDCY, the CD34+ cell count at the first apheresis was significantly higher than in the others (P<0.01), and the total CD34+ cell count also tended to be high (P=0.0933). In terms of apheresis days, two-thirds of the patients who underwent HDCY had two-day apheresis, whereas most who underwent Bor-HDCY had one-day apheresis. According to univariate analysis, Bor-HDCY (P<0.01), VRd (Bor, lenalidomide, and dexamethasone) as induction therapy (P=0.0529), and ≥VGPR before PBSCH (P=0.0767) were factors associated with a higher CD34+ cell count at first apheresis. Although multivariate analysis showed that there were no independently significant factors influencing the CD34+ cell count at the first apheresis, the stepwise selection method revealed that only the Bor-HDCY regimen remained in the final model (P<0.005). Bor-HDCY may be a useful conditioning regimen for increasing the CD34+ cell yield.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"147-153"},"PeriodicalIF":1.5,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/06/5b/jslrt-62-147.PMC9635030.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40719537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Idiopathic plasmacytic lymphadenopathy: A conceptual history along with a translation of the original Japanese article published in 1980. 特发性浆细胞性淋巴结病:一个概念的历史与翻译原日本文章发表于1980年。

IF 1.5

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2022-01-01 DOI: 10.3960/jslrt.22011

Kengo Takeuchi

引用次数: 6

Candidate biomarkers for idiopathic multicentric Castleman disease. 特发性多中心Castleman病的候选生物标志物。

IF 1.5

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2022-01-01 DOI: 10.3960/jslrt.22010

Remi Sumiyoshi, Tomohiro Koga, Atsushi Kawakami

引用次数: 4

Castleman disease and mimickers: Clinicopathological findings of atypical lymphoproliferative disorders associated with autoimmune disease. Castleman病和模仿:与自身免疫性疾病相关的非典型淋巴增生性疾病的临床病理表现

IF 1.5

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2022-01-01 DOI: 10.3960/jslrt.22025

Yoshimasa Nakazato, Shigeru Tsuchida, Atsuko Takada-Owada, Masato Onozaki, Shuhei Noda, Yumi Nozawa, Mina Takaoka, Kazuyuki Ishida

{"title":"Castleman disease and mimickers: Clinicopathological findings of atypical lymphoproliferative disorders associated with autoimmune disease.","authors":"Yoshimasa Nakazato, Shigeru Tsuchida, Atsuko Takada-Owada, Masato Onozaki, Shuhei Noda, Yumi Nozawa, Mina Takaoka, Kazuyuki Ishida","doi":"10.3960/jslrt.22025","DOIUrl":"https://doi.org/10.3960/jslrt.22025","url":null,"abstract":"Atypical lymphoproliferative disorders (LPDs) related with autoimmune disease (AID) show marked clinicopathological diversity, which are defined as three distinct clinicopathological subtypes such as those resembling Castleman disease (CD), atypical paracortical hyperplasia with lymphoid follicles (APHLF), and atypical lymphoplasmacytic and immunoblastic proliferation (ALPIB). We studied excisional biopsy specimens from 31 patients with atypical LPDs associated with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and Sjögren syndrome (SjS). The lesions in these 31 cases were classified into 6 (19.4%) cases resembling CD, 14 (45.2%) cases of APHLF, and 11 (35.5%) cases of ALPIB. Five cases (83.3%) resembling CD were in the active stage with systemic symptoms and multicentric lymphadenopathy. Thirteen cases (92.9%) of APHLF showed systemic symptoms, multicentric lymphadenopathy and abnormal laboratory findings. Histologic findings for cases resembling CD were rare in patients with RA and SjS. In AID patients, histologic findings for cases resembling CD or APHLF findings correlated with disease activity and multicentric lymphadenopathy. Six cases (54.5%) of ALPIB were in the active phase with systemic symptoms and multicentric lymphadenopathy. ALPIB tended to be unrelated to AID activity, especially in the majority of patients with no abnormal laboratory findings. Atypical LPDs associated with AID is a group of diseases that may be overdiagnosed and overtreated. The diagnosis of atypical LPDs associated with AID requires an understanding of the histological findings as well as a comprehensive assessment of the presence of systemic symptoms, the distribution of lymphadenopathy, and abnormal laboratory findings.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"119-126"},"PeriodicalIF":1.5,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/81/4e/jslrt-62-119.PMC9635029.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40381595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Lymphoma Microenvironment in DLBCL and PTCL-NOS: the key to uncovering heterogeneity and the potential for stratification. DLBCL和PTCL-NOS的淋巴瘤微环境:揭示异质性和潜在分层的关键。

IF 1.5

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2022-01-01 DOI: 10.3960/jslrt.22027

Kohta Miyawaki, Takeshi Sugio

{"title":"Lymphoma Microenvironment in DLBCL and PTCL-NOS: the key to uncovering heterogeneity and the potential for stratification.","authors":"Kohta Miyawaki, Takeshi Sugio","doi":"10.3960/jslrt.22027","DOIUrl":"https://doi.org/10.3960/jslrt.22027","url":null,"abstract":"Diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) are the most common subtypes of mature B cell neoplasm and T/NK cell lymphoma, respectively. They share a commonality in that they are, by definition, highly heterogeneous populations. Recent studies are revealing more about the heterogeneity of these diseases, and at the same time, there is an active debate on how to stratify these heterogeneous diseases and make them useful in clinical practice. The various immune cells and non-cellular components surrounding lymphoma cells, i.e., the lymphoma microenvironment, have been the subject of intense research since the late 2000s, and much knowledge has been accumulated over the past decade. As a result, it has become clear that the lymphoma microenvironment, despite its paucity in tissues, significantly impacts the lymphoma pathogenesis and clinical behavior, such as its prognosis and response to therapy. In this article, we review the role of the lymphoma microenvironment in DLBCL and PTCL-NOS, with particular attention given to its impact on the prognosis and stratification.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"127-135"},"PeriodicalIF":1.5,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5a/bd/jslrt-62-127.PMC9635031.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40381596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Donor-derived diffuse large B-cell lymphoma after haploidentical stem cell transplantation for acute myeloid leukemia. 单倍体干细胞移植治疗急性髓系白血病后供体源性弥漫性大b细胞淋巴瘤。

IF 1.5

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2022-01-01 DOI: 10.3960/jslrt.22014

Anna Kawashiri, Shun-Ichiro Nakagawa, Chisato Ishiguro, Kanako Mochizuki, Yoshinobu Maeda, Toshiro Kurokawa

{"title":"Donor-derived diffuse large B-cell lymphoma after haploidentical stem cell transplantation for acute myeloid leukemia.","authors":"Anna Kawashiri, Shun-Ichiro Nakagawa, Chisato Ishiguro, Kanako Mochizuki, Yoshinobu Maeda, Toshiro Kurokawa","doi":"10.3960/jslrt.22014","DOIUrl":"https://doi.org/10.3960/jslrt.22014","url":null,"abstract":"We report a case of donor-derived diffuse large B-cell lymphoma (DLBCL), which developed 5 years after stem cell transplantation from a human leukocyte antigen (HLA)-haploidentical donor for acute myeloid leukemia (AML). A 51-year-old male was diagnosed with AML with variant KMT2A translocation involving t(6;11)(q13;q23). After 12 cycles of azacitidine treatment, fluorescence in situ hybridization (FISH) for KMT2A split signal indicated that 94% of his bone marrow (BM) cells were positive. He underwent peripheral blood stem cell transplantation (PBSCT) from his HLA-haploidentical son. The preconditioning regimen consisted of fludarabine, busulfan, melphalan, and antithymocyte globulin (ATG). The graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and short-term methotrexate. On day 28, KMT2A FISH analysis indicated that he had achieved a complete response (CR). He continued to receive tacrolimus for the limited type of cutaneous chronic GVHD. Five years after the transplantation, positron emission tomography/computed tomography (PET/CT) showed an abdominal tumor. The tumor was diagnosed as DLBCL without Epstein-Barr virus. BM aspiration revealed the infiltration of lymphoma cells with t(8;14)(q24;q32). Chimerism analysis showed that both the peripheral blood (PB) and abdominal lymphoma cells were of donor origin. After 4 cycles of salvage chemotherapy, PET/CT showed that a CR had been achieved. He underwent a second PBSCT from an HLA-identical unrelated donor. The preconditioning regimen and GVHD prophylaxis were the same as those for the first PBSCT without ATG. The patient's PB revealed complete second donor-type chimerism, and the patient has maintained a CR since the second transplantation.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"175-180"},"PeriodicalIF":1.5,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b2/3e/jslrt-62-175.PMC9635034.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40381597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Retrospective study of the utility of FLIPI/FLIPI-2 for follicular lymphoma patients treated with R-CHOP. FLIPI/FLIPI-2在R-CHOP治疗滤泡性淋巴瘤患者中的应用回顾性研究。

IF 1.5

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2012-01-01 DOI: 10.3960/jslrt.52.77

Ayumi Numata, Naoto Tomita, Katsumichi Fujimaki, Masatsugu Tanaka, Chizuko Hashimoto, Rika Oshima, Kenji Matsumoto, Shiro Matsuura, Wataru Yamamoto, Shigeki Motomura, Yoshiaki Ishigatsubo

引用次数: 8

Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy : case report. 在硼替佐米治疗期间，解决乙型肝炎感染的多发性骨髓瘤患者乙型肝炎再激活:病例报告。

IF 1.5

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2012-01-01 DOI: 10.3960/jslrt.52.67

Hiroaki Tanaka, Ikuo Sakuma, Shinichiro Hashimoto, Yusuke Takeda, Shio Sakai, Toshiyuki Takagi, Takanori Shimura, Chiaki Nakaseko

引用次数: 27

Lymph node infarction in classical Hodgkin's lymphoma. 经典霍奇金淋巴瘤的淋巴结梗死。

IF 1.5

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2012-01-01 DOI: 10.3960/jslrt.52.35

Eiichiro Mori, Yasunori Enomoto, Hirokazu Nakamine, Takahiko Kasai, Maiko Takeda, Masato Takano, Kouhei Morita, Toshizo Koizumi, Akitaka Nonomura

{"title":"Lymph node infarction in classical Hodgkin's lymphoma.","authors":"Eiichiro Mori, Yasunori Enomoto, Hirokazu Nakamine, Takahiko Kasai, Maiko Takeda, Masato Takano, Kouhei Morita, Toshizo Koizumi, Akitaka Nonomura","doi":"10.3960/jslrt.52.35","DOIUrl":"https://doi.org/10.3960/jslrt.52.35","url":null,"abstract":"Among lymphoproliferative disorders, lymph node infarction appears to be most frequently seen in diffuse large B-cell lymphoma, followed by follicular lymphoma, with other types being rare. We experienced one such case, classical Hodgkin's lymphoma (cHL) associated with lymph node infarction, in which Reed-Sternberg (RS) cells were positive for CD15, CD30, fascin, PAX-5, p53, latent membrane protein-1 (LMP-1), Bcl-2, and EBV-encoded small non-polyadenylated RNAs. Furthermore, RS cells in the infarcted area were still positive for CD30, fascin, p53, and Bcl-2. For definitive diagnosis of nodal lymphomas including Hodgkin's lymphoma, identification of the effacement of normal nodal architecture is essential. Although this could not be evaluated in our case because of predominant reactive follicular hyperplasia with interfollicular distribution of RS cells, the presence of large cells with RS cell-related molecules together with the distorted distribution of cCD3-positive cells and CD20-positive cells led us to make a definitive diagnosis of cHL. It is, therefore, considered that immunohistochemical evaluation of the infarcted lymph node is, at least on some occasions, still informative for more accurate diagnosis of lymphoid neoplasia. Hodgkin's lymphoma should also be considered when one encounters lymph node infarction.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"35-9"},"PeriodicalIF":1.5,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3960/jslrt.52.35","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30697004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4